Digoxin and ouabain induce P-glycoprotein by activating calmodulin kinase II and hypoxia-inducible factor-1α in human colon cancer cells

Toxicology and Applied Pharmacology

Volumn 240, Issue 3, 2009, Pages 385-392

  Riganti, Chiara ^a,b   Campia, Ivana ^a   Polimeni, Manuela ^a   Pescarmona, Gianpiero ^a,b   Ghigo, Dario ^a,b   Bosia, Amalia ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b Centre for Research in Experimental Medicine CeRMS   (Italy)

Author keywords

Calmodulin kinase II; Digoxin; Doxorubicin; Hypoxia inducible factor 1 ; Ouabain; P glycoprotein

Indexed keywords

CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; DIGOXIN; DOXORUBICIN; GLYCOPROTEIN P; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MULTIDRUG RESISTANCE PROTEIN 1; OUABAIN; SODIUM CALCIUM EXCHANGE PROTEIN;

APOPTOSIS; ARTICLE; CALCIUM TRANSPORT; CANCER RESISTANCE; CELL STRAIN HT29; COLON CANCER; COLON MUCOSA; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACCUMULATION; HUMAN; HUMAN CELL; INTRACELLULAR TRANSPORT; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SODIUM CELL LEVEL;

BASE SEQUENCE; BLOTTING, WESTERN; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; COLONIC NEOPLASMS; DIGOXIN; DNA PRIMERS; DOXORUBICIN; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME ACTIVATION; HT29 CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; OUABAIN; P-GLYCOPROTEIN; PHOSPHORYLATION; POLYMERASE CHAIN REACTION;

STROPHANTHUS GRATUS;

EID: 70349779184     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2009.07.026     Document Type: Article

References (37)

1. Adorisio R., De Luca L., Rossi J., and Gheorghiade M. Pharmacological treatment of chronic heart failure. Heart Fail. Rev. 11 (2006) 109-123
2. Anderson M.E. Calmodulin kinase signaling in heart: an intriguing candidate target for therapy of myocardial dysfunction and arrhythmias. Pharmacol. Ther. 106 (2005) 39-55
3. 2+ exchanger: from molecular biology to therapeutic perspectives. Pharmacol. Rev. 56 (2004) 633-654
4. Baudouin-Legros M., Brouillard F., Tondelier D., Hinzpeter A., and Edelman A. Effect of ouabain on CFTR gene expression in human Calu-3 cells. Am. J. Physiol. Cell Physiol. 284 (2003) C620-C626
5. Bodo A., Bakos E., Szeri F., Varadi A., and Sarkadi B. The role of multidrug transporters in drug availability, metabolism and toxicity. Toxicol. Lett. 140-141 (2003) 133-143
6. Brouillard F., Tondelier D., Edelman A., and Baudouin-Legros M. Drug resistance induced by ouabain via the stimulation of MDR1 gene expression in human carcinomatous pulmonary cells. Cancer Res. 61 (2001) 1693-1698
7. Chomczynski P., and Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162 (1987) 156-159
8. Comerford K.M., Wallace T.J., Karhausen J., Louis N.A., Montalto M.C., and Colgan S.P. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 62 (2002) 3387-3394
9. Cortes-Funes H., and Coronado C. Role of anthracyclines in the era of targeted therapy. Cardiovasc. Toxicol. 7 (2007) 56-60
10. de Lange E.C. Potential role of ABC transporters as a detoxification system at the blood-CSF barrier. Adv. Drug Deliv. Rev. 56 (2004) 1793-1809
11. Geick A., Eichelbaum M., and Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J. Biol. Chem. 276 (2001) 14581-14587
12. Hallam T.J., Sanchez A., and Rink T.J. Stimulus-response coupling in human platelets. Changes evoked by platelet-activating factor in cytoplasmic free calcium monitored with the fluorescent calcium indicator quin2. Biochem. J. 218 (1984) 819-827
13. Haslam I.S., Jones K., Coleman T., and Simmons N.L. Rifampin and digoxin induction of MDR1 expression and function in human intestinal (T84) epithelial Cells. Br. J. Pharmacol. 154 (2008) 246-255
14. Huang L., Li H., and Xie Z. Ouabain-induced hypertrophy in cultured cardiac myocytes is accompanied by changes in expression of several late response genes. J. Mol. Cell. Cardiol. 29 (1997) 429-437
15. Hui A.S., Bauer A.L., Striet J.B., Schnell P.O., and Czyzyk-Krzeska M.F. Calcium signaling stimulates translation of HIF-1alpha during hypoxia. FASEB J. 20 (2006) 466-475
16. Kaplan J. H. Biochemistry of Na,K-ATPase. Annu. Rev. Biochem. 71 (2002) 511-535
17. +-ATPase in human breast cancer cells. Mol. Pharmacol. 67 (2005) 929-936
18. + channels in endothelial and vascular smooth muscle cells. Eur. J. Pharmacol. 582 (2008) 35-41
19. Liu Y.V., Hubbi M.E., Pan F., McDonald K.R., Mansharamani M., Cole R.N., Liu J.O., and Semenza G.L. Calcineurin promotes hypoxia-inducible factor 1α expression by dephosphorylating RACK1 and blocking RACK1 dimerization. J. Biol. Chem. 282 (2007) 37064-37073
20. Nasu S., Milas L., Kawabe S., Raju U., and Newman R.A. Enhancement of radiotherapy by oleandrin is a caspase-3 dependent process. Cancer Lett. 185 (2002) 145-151
21. O'Donnell J.L., Joyce M.R., Shannon A.M., Harmey J., Geraghty J., and Bouchier-Hayes D. Oncological implications of hypoxia inducible factor-1alpha (HIF-1alpha) expression. Cancer Treat. Rev. 32 (2006) 407-416
22. Prassas I., and Diamandis E.P. Novel therapeutic applications of cardiac glycosides. Nat. Rev. Drug Discov. 7 (2008) 926-935
23. Raghavendra P.B., Sreenivasan Y., Ramesh GT., and Manna S.K. Cardiac glycoside induces cell death via FasL by activating calcineurin and NF-AT, but apoptosis initially proceeds through activation of caspases. Apoptosis 12 (2007) 307-318
24. Reeves W.C., Griffith J.W., Wood M.A., and Whitesell L. Exacerbation of doxorubicin cardiotoxicity by digoxin administration in an experimental rabbit model. Int. J. Cancer 45 (1990) 731-736
25. Riganti C., Miraglia E., Viarisio D., Costamagna C., Pescarmona G.P., Ghigo D., and Bosia A. Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux. Cancer Res. 65 (2005) 516-525
26. Riganti C., Doublier S., Aldieri E., Orecchia S., Betta P.G., Gazzano E., Ghigo D., and Bosia A. Asbestos induces doxorubicin resistance in MM98 mesothelioma cells via HIF-1α. Eur. Respir. J. 32 (2008) 443-451
27. Riganti C., Doublier S., Viarisio D., Miraglia E., Pescarmona G., Ghigo D., and Bosia A. Artemisinin induces doxorubicin resistance in human colon cancer cells via calcium-dependent activation of HIF-1alpha and P-glycoprotein overexpression. Br. J. Pharmacol. 156 (2009) 1054-1066
28. Schoner W., and Scheiner-Bobis G. Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth. Am. J. Physiol. Cell Physiol. 293 (2007) 509-536
29. Sodhi A., Montaner S., Miyazaki H., and Gutkind J.S. MAPK and Akt act cooperatively but independently on hypoxia inducible factor-1alpha in rasV12 upregulation of VEGF. Biochem. Biophys. Res. Commun. 287 (2001) 292-300
30. Somberg J., Cagin N., Levitt B., Bounous H., Ready P., Leonard D., and Anagnostopoulos C. Blockade of tissue uptake of the antineoplastic agent, doxorubicin. J. Pharmacol. Exp. Ther. 204 (1978) 226-231
31. Takara K., Sakaeda T., and Okumura K. An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Curr. Pharm. Des. 12 (2006) 273-286
32. Whittaker J.A., and Al-Ismail S.A.D. Effect of digoxin and vitamin E in preventing cardiac damage caused by doxorubicin in acute myeloid leukemia. Br. Med. J. 288 (1984) 283-284
33. Wibom R., Hagenfeldt L., and von Dobeln U. Measurement of ATP production and respiratory chain enzyme activities in mitochondria isolated from small muscle biopsy samples. Anal. Biochem. 311 (2002) 139-151
34. Winnicka K., Bielawski K., Bilewaska A., and Surazynski A. Antiproliferative activity of derivatives of ouabain, digoxin and proscillaridin A in human MCF-7 and MDA-MB-231 breast cancer cells. Biol. Pharm. Bull. 31 (2008) 1131-1140
35. ++/calmodulin kinase-dependent activation of hypoxia inducible factor 1 transcriptional activity in cells subjected to intermittent hypoxia. J. Biol. Chem. 280 (2005) 4321-4328
36. Zhang H., Qian D.Z., Tan Y.S., Lee K.A., Gao P., Ren Y.R., Rey S., Hammers H., Chang D., Pili R., Dang C.V., Liu J.O., and Semenza G.L. Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 19579-19586
37. 2+/calmodulin kinase II. J Clin. Invest. 111 (2003) 617-625